There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Inovio Pharmaceuticals (INO – Research Report) with bullish sentiments.
Merck & Company (MRK)
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company, with a price target of $150.00. The company’s shares closed last Monday at $129.29, close to its 52-week high of $133.10.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $139.54.
See the top stocks recommended by analysts >>
Inovio Pharmaceuticals (INO)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $18.00. The company’s shares closed last Monday at $11.36.
According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of
Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.00, representing a 49.8% upside. In a report released yesterday, Stephens also assigned a Buy rating to the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRK:
